Adaptive Biotechnologies Corp (ADPT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q4 '18: 55.7M Q1 '19: 58.6M Q2 '19: 69.2M Q3 '19: 78.1M Q4 '19: 85.1M Q1 '20: 93.3M Q2 '20: 92.2M Q3 '20: 92.4M Q4 '20: 98.4M Q1 '21: 115.9M Q2 '21: 133.4M Q3 '21: 146.6M Q4 '21: 154.3M Q1 '22: 154.5M Q2 '22: 159.7M Q3 '22: 168M Q4 '22: 185.3M Q1 '23: 184.3M Q2 '23: 189.6M Q3 '23: 179.7M Q4 '23: 170.3M Q1 '24: 174.5M Q2 '24: 168.8M Q3 '24: 177.3M Q4 '24: 179M Q1 '25: 189.5M Q2 '25: 205.2M Q3 '25: 252.8M Q4 '25: 277M Q1 '26: 295.4M Q2 '26: 308.1M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 80M 160M 240M Q4 '18: 36M Q1 '19: 37.9M Q2 '19: 47.8M Q3 '19: 56.5M Q4 '19: 62.8M Q1 '20: 70.7M Q2 '20: 70.4M Q3 '20: 70.1M Q4 '20: 75.9M Q1 '21: 88.7M Q2 '21: 100.4M Q3 '21: 105.4M Q4 '21: 105M Q1 '22: 102M Q2 '22: 104.7M Q3 '22: 112.4M Q4 '22: 127.4M Q1 '23: 120.9M Q2 '23: 121.5M Q3 '23: 107.2M Q4 '23: 94.7M Q1 '24: 99.6M Q2 '24: 92.4M Q3 '24: 103.6M Q4 '24: 106.9M Q1 '25: 118.5M Q2 '25: 135.5M Q3 '25: 181.6M Q4 '25: 205.6M Q1 '26: 222.3M Q2 '26: 232.8M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '18: -49.8M Q1 '19: -56.7M Q2 '19: -59.5M Q3 '19: -68.3M Q4 '19: -78.4M Q1 '20: -93M Q2 '20: -113.8M Q3 '20: -132.8M Q4 '20: -152.8M Q1 '21: -159.5M Q2 '21: -172.3M Q3 '21: -191.6M Q4 '21: -209M Q1 '22: -230.8M Q2 '22: -233.5M Q3 '22: -222.6M Q4 '22: -200.2M Q1 '23: -194.3M Q2 '23: -189.6M Q3 '23: -195.2M Q4 '23: -227M Q1 '24: -218.6M Q2 '24: -218.1M Q3 '24: -199.8M Q4 '24: -162.5M Q1 '25: -143.4M Q2 '25: -121.1M Q3 '25: -78.2M Q4 '25: -57.1M Q1 '26: -46.7M Q2 '26: -37.5M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '18: -46.4M Q1 '19: -52.4M Q2 '19: -55.6M Q3 '19: -61.3M Q4 '19: -68.6M Q1 '20: -81.6M Q2 '20: -99.5M Q3 '20: -122.3M Q4 '20: -146.2M Q1 '21: -155.5M Q2 '21: -171.2M Q3 '21: -190.4M Q4 '21: -207.3M Q1 '22: -229.4M Q2 '22: -232.1M Q3 '22: -221.5M Q4 '22: -200.2M Q1 '23: -195.2M Q2 '23: -190.9M Q3 '23: -195.9M Q4 '23: -225.2M Q1 '24: -215.1M Q2 '24: -213.5M Q3 '24: -195.2M Q4 '24: -159.5M Q1 '25: -141.8M Q2 '25: -121.2M Q3 '25: -79.6M Q4 '25: -59.5M Q1 '26: -49.7M Q2 '26: -63.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

0 30M 60M 90M Q4 '18: 19.7M Q1 '19: 20.7M Q2 '19: 21.4M Q3 '19: 21.6M Q4 '19: 22.3M Q1 '20: 22.6M Q2 '20: 21.8M Q3 '20: 22.3M Q4 '20: 22.5M Q1 '21: 27.2M Q2 '21: 33M Q3 '21: 41.2M Q4 '21: 49.3M Q1 '22: 52.5M Q2 '22: 55M Q3 '22: 55.7M Q4 '22: 57.9M Q1 '23: 63.4M Q2 '23: 68.1M Q3 '23: 72.5M Q4 '23: 75.6M Q1 '24: 74.9M Q2 '24: 76.3M Q3 '24: 73.7M Q4 '24: 72.1M Q1 '25: 71M Q2 '25: 69.7M Q3 '25: 71.2M Q4 '25: 71.4M Q1 '26: 73.1M Q2 '26: 75.3M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '19: 245.2M Q3 '19: 226.8M Q4 '19: 205.4M Q1 '20: -104.5M Q2 '20: -119.6M Q3 '20: -136.6M Q4 '20: -149.7M Q1 '21: -176.3M Q2 '21: -182.5M Q3 '21: -178.7M Q4 '21: -192.7M Q1 '22: -198.9M Q2 '22: -208.8M Q3 '22: -207.8M Q4 '22: -183.9M Q1 '23: -178.6M Q2 '23: -155.1M Q3 '23: -159.4M Q4 '23: -156.3M Q1 '24: -135.5M Q2 '24: -129.3M Q3 '24: -109.7M Q4 '24: -95.2M Q1 '25: -85.3M Q2 '25: -80.5M Q3 '25: -60.5M Q4 '25: -46M Q1 '26: -27M Q2 '26: -21M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '19: 235.2M Q3 '19: 215.5M Q4 '19: 194.2M Q1 '20: -114.8M Q2 '20: -130.7M Q3 '20: -148.5M Q4 '20: -168.5M Q1 '21: -208M Q2 '21: -233.9M Q3 '21: -240.6M Q4 '21: -254.5M Q1 '22: -247.9M Q2 '22: -241M Q3 '22: -230.8M Q4 '22: -200.3M Q1 '23: -194.8M Q2 '23: -169.7M Q3 '23: -171.4M Q4 '23: -167M Q1 '24: -144.8M Q2 '24: -136.6M Q3 '24: -114.5M Q4 '24: -98.9M Q1 '25: -88.8M Q2 '25: -82.8M Q3 '25: -62.9M Q4 '25: -48.9M Q1 '26: -29.5M Q2 '26: -24M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '21: 140.4M Q3 '21: 140.8M Q1 '22: 141.7M Q2 '22: 142.4M Q3 '22: 142.9M Q1 '23: 143.5M Q2 '23: 144.4M Q3 '23: 144.7M Q1 '24: 145.8M Q2 '24: 147.4M Q3 '24: 147.5M Q1 '25: 149.2M Q2 '25: 152.1M Q3 '25: 163.2M Q1 '26: 155.5M Q2 '26: 159.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '18: -3.67 Q1 '19: -4.12 Q2 '19: -4.34 Q3 '19: -3.79 Q4 '19: -1.01 Q1 '20: 0.19 Q2 '20: 1.16 Q3 '20: 1.00 Q4 '20: -1.10 Q1 '21: -1.14 Q2 '21: -1.23 Q3 '21: -1.36 Q4 '21: -1.48 Q1 '22: -1.63 Q2 '22: -1.65 Q3 '22: -1.57 Q4 '22: -1.41 Q1 '23: -1.37 Q2 '23: -1.33 Q3 '23: -1.36 Q4 '23: -1.56 Q1 '24: -1.49 Q2 '24: -1.47 Q3 '24: -1.34 Q4 '24: -1.08 Q1 '25: -0.95 Q2 '25: -0.81 Q3 '25: -0.53 Q4 '25: -0.40 Q1 '26: -0.33 Q2 '26: -0.41 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.